Krystal Biotech, Inc. (KRYS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. At $259.77, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 5.7%; Concentration risk — Product: VYJUVEK.
Krystal Biotech is a commercial-stage biotechnology company using an HSV-1-based gene therapy platform. VYJUVEK is approved in the US, EU, and Japan for dystrophic epidermolysis bullosa (DEB); it launched in the US in 2023 and in Europe and Japan in 2025. The company also has a... Read more
Sell if holding. At $259.77, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 5.7%; Concentration risk — Product: VYJUVEK. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 4d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductVYJUVEK10-K Item 1A: 'our near-term prospects, including our ability to develop our product candidates and generate revenue, and our future growth are substantially dependent on the commercial success of VYJUVEK'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $259.77, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 5.7%; Concentration risk — Product: VYJUVEK. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $244.73. Score 5.2/10, moderate confidence.
Take-profit target: $274.05 (+5.7% upside). Prior stop was $244.73. Stop-loss: $244.73.
Concentration risk — Product: VYJUVEK; Thin upside margin: 5.7%; Earnings in 4 days (event risk).
Krystal Biotech, Inc. trades at a P/E of 38.0 (forward 25.5). TrendMatrix value score: 3.5/10. Verdict: Sell.
18 analysts cover KRYS with a consensus score of 4.3/5. Average price target: $315.
What does Krystal Biotech, Inc. do?Krystal Biotech is a commercial-stage biotechnology company using an HSV-1-based gene therapy platform. VYJUVEK is...
Krystal Biotech is a commercial-stage biotechnology company using an HSV-1-based gene therapy platform. VYJUVEK is approved in the US, EU, and Japan for dystrophic epidermolysis bullosa (DEB); it launched in the US in 2023 and in Europe and Japan in 2025. The company also has a pipeline of clinical and pre-clinical candidates.